Marker Therapeutics, Inc.

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-23 pm EDT			5-day change	1st Jan Change
1.420 ^USD	-2.07%		-6.58%	-54.34%

May. 29	Marker Therapeutics, Inc. - Special Call
May. 20	Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	CI

Marker Therapeutics, Inc. Announces Resignation of John Wilson from the Board of Directors

Published on 01/30/2025 at 16:05

On January 24, 2025, Mr. John Wilson resigned from the Board of Directors of Marker Therapeutics, Inc.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	REECE LIMITED	16.86AUD	+1.75%	+3.95%	6.89B
	MARKER THERAPEUTICS, INC.	1.420USD	-2.07%	-6.58%	16.07M

Latest news about Marker Therapeutics, Inc.

Marker Therapeutics, Inc. - Special Call	May. 29
Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	May. 20	CI
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	May. 20	RE
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 15	CI
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 31	CI
Marker Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	Mar. 30	CI
Canaccord Genuity Initiates Marker Therapeutics at Buy With $8 Price Target	Mar. 05	MT
Marker Therapeutics, Inc. Announces Resignation of John Wilson from the Board of Directors	Jan. 30	CI
Marker Therapeutics, Inc. announced that it has received $16.1 million in funding	Dec. 22	CI
Marker Therapeutics to Raise $16.1 Million in Private Placement	Dec. 19	MT
Marker Therapeutics, Inc. Provides Clinical Update on MT-601 in Patients with Lymphoma	Dec. 19	CI
Marker Therapeutics, Inc. announced that it expects to receive $16.1 million in funding	Dec. 18	CI
Marker Therapeutics Receives $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas to Support the Investigation of Mt-601 in Patients with Pancreatic Cancer	Dec. 17	CI
Marker Therapeutics Files $300 Million Mixed Shelf	Nov. 27	MT
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $1.9M	Nov. 14	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 14	CI
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-14	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q2 Revenue $1.2M	24-08-14	MT
Marker Therapeutics Gets $2 Million Grant From National Institutes of Health	24-08-12	MT
Marker Therapeutics, Inc. Receives $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients with Non-Hodgkin?s Lymphoma	24-08-12	CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Index	24-06-30	CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Index	24-06-30	CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Growth Index	24-06-30	CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Growth Index	24-06-30	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	24-05-15	MT

Chart Marker Therapeutics, Inc.

Duration

Period

MRKR: Dynamic Chart

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Employees

Sector

Biotechnology & Medical Research

Calendar

Aug. 17 - Q2 2025 Earnings Release (Projected)

More about the company